Nancy J. Hutson

Dr. Nancy J. Hutson served as Senior Vice President, Pfizer Global R&D and Director of Pfizer's largest pharmaceutical R&D site in Connecticut, where she led a team of 4,500 (primarily scientists) with a budget in excess of $1 billion annually. This was a time of tremendous growth for Pfizer leading to the discovery and development of dozens of important medicines. Earlier in her career at Pfizer, Dr Hutson built the Department of Metabolic Disease which had research in diabetes, obesity, osteoporosis, and cardiovascular including modulating lipids and anti-hypertensives. After leaving Pfizer in 2006, Dr. Hutson went on to leverage her in-depth knowledge and understanding of research, drug development and business issues in a variety of both large and small biopharmaceutical companies. Currently, Dr. Hutson serves as a board member of Endo International, plc (ENDP), BioCryst Pharmaceuticals, Inc. (BCRX) and PhaseBio Pharmaceuticals, Inc (PHAS). She was previously a Director of both Cubist Pharmaceuticals until 2015, when it was purchased by Merck ($8.4B) and Inspire Pharmaceuticals, Inc. until 2011 (also acquired by Merck). In these positions Dr. Hutson has gained in-depth biotechnology Board experience and has been able to aid biotech companies in mastering the complexities of drug discovery and development.

Dr. Hutson has received many professional honors during her career. Most recently she was named one of the most influential Female Directors by Women, Inc Magazine, November 2019. Dr. Hutson holds a Bachelor of Arts degree from Illinois Wesleyan University and a Ph.D. degree from Vanderbilt University. She completed a Postdoctoral fellowship in Biochemistry at University of Oxford.